Loading clinical trials...
Loading clinical trials...
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Conditions
Interventions
Lenvatinib
Pembrolizumab
+3 more
Locations
205
United States
Arizona Oncology Associates PC- HOPE ( Site 0770)
Tucson, Arizona, United States
Scripps Clinic Torrey Pines ( Site 0714)
La Jolla, California, United States
USC Norris Comprehensive Cancer Center ( Site 0717)
Los Angeles, California, United States
UCLA Hematology/Oncology - Santa Monica ( Site 0720)
Los Angeles, California, United States
UC Irvine Health ( Site 0718)
Orange, California, United States
Yale Cancer Center ( Site 0724)
New Haven, Connecticut, United States
Start Date
May 22, 2020
Primary Completion Date
August 19, 2025
Completion Date
March 23, 2026
Last Updated
April 22, 2026
NCT06571396
NCT06454578
NCT05870969
NCT02221778
NCT05389527
NCT05908786
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions